Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis.

Life (Basel, Switzerland)·2026

Same author

Generation of high-expressing transposon-based stable pools to produce (1 + 1) and (2 + 1) bispecific common light chain antibodies.

Biotechnology progress·2026

Same author

Early Keratometric and Scheimpflug Topographic Stabilization after Pterygium Excision with Conjunctival Autograft: A Prospective Cohort Study.

Romanian journal of ophthalmology·2026

Same author

Editorial: Microalgae-microbe interactions: advances and applications.

Frontiers in microbiology·2026

Same author

Differential Cytokine Profiles in Prostate Cancer Under Treatment: Implications for Prognosis and Synergistic Therapy Design.

Cancers·2026

Same author

Simufilam in Alzheimer's Disease: Assessment of Efficacy of a Controversial Drug in Human Neuronal Cell Culture.

Pharmaceuticals (Basel, Switzerland)·2026

Search research articles

Related Experiment Video

Updated: Feb 25, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Itolizumab in Psoriasis.

Ankita Srivastava¹

¹Department of Skin and VD, JNU Institute for Medical Sciences and Research Centre, Jaipur, Rajasthan, India.

Indian Journal of Dermatology

|August 11, 2017

Summary

This summary is machine-generated.

Itolizumab, an anti-CD6 monoclonal antibody, is approved in India for psoriasis treatment. While safe, its comparative benefits and potential for other immune disorders require further study.

Keywords:

Anti-CD6 monoclonal antibody itolizumab psoriasis treatment

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

Related Experiment Videos

Last Updated: Feb 25, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination

Published on: February 9, 2021

Area of Science:

Immunology
Dermatology
Pharmacology

Background:

Psoriasis is a chronic immune-mediated condition managed with various biologics.
Itolizumab, an anti-CD6 monoclonal antibody, is an approved biologic treatment in India.
Understanding Itolizumab's mechanism and comparative efficacy is crucial.

Purpose of the Study:

To review the current status of Itolizumab in psoriasis treatment.
To discuss its mechanism of action, safety profile, and place among other therapies.
To explore potential applications in other immune-mediated disorders.

Main Methods:

Literature review of Itolizumab's clinical data and pharmacological studies.
Comparative analysis of Itolizumab with existing psoriasis biologics and immunosuppressants.
Exploration of emerging research on Itolizumab's utility in other immune conditions.

Main Results:

Itolizumab is an anti-CD6 monoclonal antibody targeting the SRCR distal domain 1.
It has demonstrated a generally safe profile, with infusion reactions being the most frequent adverse effect.
Further clinical data is needed to establish its advantages and disadvantages against other treatments.

Conclusions:

Itolizumab is a viable therapeutic option for psoriasis in India.
Establishing its comparative effectiveness and safety is essential for wider clinical adoption.
Investigating Itolizumab's efficacy in other immune-mediated diseases presents a promising research avenue.